Pharma Medico Group

What Pharma Medico Group does

Pharma Medico Group (legal entity Pharma Medico ApS) is a Danish, family-controlled, privately held pharmaceutical manufacturer founded in 1978 and headquartered in Aarhus, Denmark. It develops and commercialises dermatology therapies derived from 45+ years of research into human proteoglycan function, operating as a self-described top-three global leader in its dermatological categories across 77+ countries with 1,500+ employees.

Its proprietary technology platform — Proteoglycan Replacement Therapy (PRT) — targets Proteoglycan Atrophies as causal pathologies, addressing Proteoglycan Follicular Atrophy in hair growth disorders and Epidermal Dysglycania in age/sun-damaged skin, psoriasis, eczema, and dermatitis. A patented production process underpins proprietary delivery technologies designed to optimise bioavailability and efficacy, and the company reports a portfolio of 3,300+ intellectual property rights supporting these originator therapies. Three core brands anchor the portfolio: Nourkrin (hair growth), Nourella (skin repair and rejuvenation with next-generation retinoids), and Zymbilan (chronic inflammatory skin disease).

The business model is a channel-partnered, multi-tier global distribution play: pharma preparations and raw materials are produced at eight facilities across Scandinavia/Europe, Asia, MENA, and South America; therapies are routed through regional, national, and local representations, blue chip in-licensing and distribution partners, own national distribution entities, and major retail chains, reaching 500,000+ commercial locations worldwide. Customers are primarily healthcare professionals (dermatologists, trichologists) who prescribe the brands as monotherapy or adjunctive treatments, and downstream consumers access them via retail. The research pipeline targets further dermatological indications including skin cancer, herpes, acne, and pigmentation disorders.

Name

Pharma Medico Group

Legal name

Pharma Medico ApS

Website

https://pharmamedico.com

Company type

Private

Founded year

1978

Operating status

Operating

Short description

Pharma Medico Group is a Danish, family-controlled pharmaceutical manufacturer founded in 1978, developing Proteoglycan Replacement Therapies for dermatological disorders including hair loss, skin ageing, and inflammatory skin disease, sold across 77+ countries under the Nourkrin, Nourella, and Zymbilan brands.

Ownership category

akta.pro rank

Product category

Dermatological Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Dermatological pharmaceuticals
• Proteoglycan replacement therapy
• Hair growth treatments
• Skin repair therapies
• Pharmaceutical manufacturing

Headquarters

HQ city

Aarhus

HQ country

Denmark

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Preparations and Raw Materials: Manufacturer of pharmaceutical preparations and raw materials implemented in products. Global leader within dermatological categories with therapies including Nourkrin (hair growth), Nourella (skin repair), and Zymbilan (psoriasis/eczema/dermatitis).

Go-to-market motion1 record

Distribution channels4 records

Marketing channels1 record

Core offering

Pharma Medico Group is a manufacturer of pharmaceutical preparations and raw materials, specializing in dermatological therapies developed through Applied Proteoglycan Research. The company develops and markets biologically active originator therapies addressing Proteoglycan Atrophies, with core brands Nourkrin (hair growth disorders), Nourella (age and sun damaged skin), and Zymbilan (psoriasis, eczema, and dermatitis). Production is conducted at eight facilities across Scandinavia, Europe, Asia, MENA, and South America, with therapies distributed in over 500,000 commercial locations across 77+ countries.

Product overview

Pharma Medico Group offers a portfolio of three distinct dermatological therapy brands developed through Applied Proteoglycan Research. The core offerings include Nourkrin for hair growth disorders (addressing Proteoglycan Follicular Atrophy), Nourella for skin repair and rejuvenation (Proteoglycan Replacement Therapy with next-generation retinoids), and Zymbilan for chronic inflammatory skin conditions (addressing Epidermal Dysglycania). These therapies are biologically active, enable long-term use, and work to restore biological balance and normal biological function rather than merely addressing symptoms. The company operates globally with products available in over 500,000 commercial locations worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Nourkrin: Hair Growth Disorders - Addresses Proteoglycan Follicular Atrophy. Preferred by dermatologists, trichologists, and health care professionals as monotherapy and in combination with other products.
• Nourella
• Zymbilan

Products and services

• Nourkrin

Quantifiable outcome

• Available in over 500,000 commercial locations globally
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Blue Chip In-licensing and Distribution PartnerscoreChannel Partner/ Reseller/ DistributorLocal blue chip in-licensing and distribution partners working closely with regional and national representations. These strategic partnerships extend global reach and complement the Group's own national distribution entities. The ethos underscores the importance of geographical representation in countries where the company does business.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Aclaris Therapeutics: Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on immuno-inflammatory and dermatological diseases. It represents an emerging, science-driven dermatology peer targeting similar inflammatory skin conditions as Zymbilan.
• Hims & Hers Health: Hims & Hers is a direct-to-consumer telehealth and wellness platform offering hair-loss and skincare treatments. It is an emerging competitor in the hair-growth category where Nourkrin operates, though it relies on a digital-first model rather than prescriber channels.
• Vyome Therapeutics: Vyome Therapeutics is an emerging clinical-stage dermatology company developing therapies for inflammatory skin diseases and skin cancers. Its pipeline orientation toward dermatology indications is comparable to Pharma Medico's research pipeline expansion areas.

Broad incumbents

• Almirall: Almirall is a European-headquartered pharmaceutical company focused on dermatology, offering prescription products for skin diseases. It overlaps with Zymbilan in psoriasis, eczema, and dermatitis, and competes in the same prescriber-driven dermatology market.
• Bayer Consumer Health: Bayer's consumer health division markets dermatology and self-care brands globally. As a broad incumbent, Bayer competes in adjacent dermatology and hair-care categories with substantially larger marketing and distribution budgets than Pharma Medico.
• La Roche-Posay (L'Oréal Dermatological Beauty): La Roche-Posay, part of L'Oréal's dermatological beauty division, is a major global dermo-cosmetic brand for sensitive, aging, and inflammatory skin conditions. It overlaps with Nourella and Zymbilan in skincare for eczema, dermatitis, and sun-damaged skin, though it operates at much larger scale.

Direct peers

• Viviscal (brand) / Church & Dwight competitor Nutraceutical Wellness: Viviscal is a hair-growth supplement brand positioned similarly to Nourkrin in addressing thinning hair through nutritional intervention. It is one of the most directly comparable hair-loss brands in the same consumer and professional channels.
• Galderma: Galderma is a global dermatology-focused pharmaceutical company with branded prescription and aesthetic products. It is a direct competitor to Pharma Medico in dermatology categories, with overlapping prescriber base (dermatologists) and similar go-to-market through healthcare professionals.
• Pierre Fabre Dermatologie: Pierre Fabre's dermatology division develops and markets pharmaceutical and dermo-cosmetic products for skin and hair disorders globally. It competes with Pharma Medico's Nourella and Nourkrin brands across prescription dermatology and dermo-cosmetic channels.
• Church & Dwight (Viviscal): Church & Dwight owns Viviscal, a leading hair-growth supplement brand, putting it in direct competition with Pharma Medico's Nourkrin. Both target the same hair loss and thinning category through similar retail and professional channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma Medico Group